Name | Number of supported studies | Average coverage | |
---|---|---|---|
platelet | 9 studies | 45% ± 16% | |
megakaryocyte | 5 studies | 78% ± 9% | |
endothelial cell of sinusoid | 3 studies | 37% ± 7% |
Insufficient scRNA-seq data for expression of CLEC1B at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 98% | 581.56 | 221 / 226 | 5% | 0.16 | 22 / 406 |
spleen | 100% | 155.49 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 2.87 | 1 / 1 |
lung | 98% | 126.21 | 566 / 578 | 2% | 0.04 | 20 / 1155 |
peripheral blood | 81% | 205.95 | 750 / 929 | 0% | 0 | 0 / 0 |
adrenal gland | 63% | 18.32 | 162 / 258 | 0% | 0 | 0 / 230 |
adipose | 45% | 11.01 | 541 / 1204 | 0% | 0 | 0 / 0 |
heart | 18% | 2.90 | 154 / 861 | 0% | 0 | 0 / 0 |
breast | 17% | 2.76 | 79 / 459 | 1% | 0.01 | 6 / 1118 |
intestine | 17% | 2.75 | 164 / 966 | 0% | 0.00 | 1 / 527 |
kidney | 12% | 3.17 | 11 / 89 | 1% | 0.02 | 8 / 901 |
stomach | 12% | 1.63 | 43 / 359 | 1% | 0.02 | 3 / 286 |
esophagus | 11% | 1.73 | 153 / 1445 | 2% | 0.04 | 3 / 183 |
skin | 11% | 1.67 | 190 / 1809 | 1% | 0.02 | 4 / 472 |
thymus | 10% | 1.43 | 68 / 653 | 0% | 0 | 0 / 605 |
blood vessel | 10% | 1.82 | 133 / 1335 | 0% | 0 | 0 / 0 |
bladder | 5% | 0.52 | 1 / 21 | 4% | 0.09 | 21 / 504 |
uterus | 8% | 1.14 | 14 / 170 | 1% | 0.01 | 3 / 459 |
prostate | 9% | 1.23 | 21 / 245 | 0% | 0 | 0 / 502 |
pancreas | 4% | 0.72 | 14 / 328 | 2% | 0.08 | 4 / 178 |
ovary | 4% | 0.77 | 8 / 180 | 0% | 0.01 | 2 / 430 |
muscle | 2% | 0.25 | 15 / 803 | 0% | 0 | 0 / 0 |
brain | 1% | 0.20 | 30 / 2642 | 0% | 0 | 0 / 705 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
GO_0007165 | Biological process | signal transduction |
GO_0030220 | Biological process | platelet formation |
GO_0006952 | Biological process | defense response |
GO_0007166 | Biological process | cell surface receptor signaling pathway |
GO_0009986 | Cellular component | cell surface |
GO_0005886 | Cellular component | plasma membrane |
GO_0004888 | Molecular function | transmembrane signaling receptor activity |
GO_0030246 | Molecular function | carbohydrate binding |
GO_0005515 | Molecular function | protein binding |
Gene name | CLEC1B |
Protein name | C-type lectin domain family 1 member B C-type lectin domain family 1 member B (C-type lectin-like receptor 2) (CLEC-2) |
Synonyms | CLEC2 UNQ721/PRO1384 |
Description | FUNCTION: C-type lectin-like receptor that functions as a platelet receptor for the lymphatic endothelial marker, PDPN . After ligand activation, signals via sequential activation of SRC and SYK tyrosine kinases leading to activation of PLCG2 . .; FUNCTION: (Microbial infection) Acts as a receptor for the platelet-aggregating snake venom protein rhodocytin. Rhodocytin binding leads to tyrosine phosphorylation and this promotes the binding of spleen tyrosine kinase (SYK) and initiation of downstream tyrosine phosphorylation events and activation of PLCG2 . .; FUNCTION: (Microbial infection) Acts as an attachment factor for Human immunodeficiency virus type 1 (HIV-1) and facilitates its capture by platelets . . |
Accessions | ENST00000298527.11 [Q9P126-1] ENST00000428126.6 [Q9P126-2] ENST00000398937.6 H7BYT7 ENST00000348658.4 [Q9P126-2] Q9P126 |